Background: People with severe mental illness (SMI) have high rates of chronic disease and premature
Introduction
People with severe mental illness (SMI), including schizophrenia, schizophrenia-like disorders, bipolar and severe affective disorders, on average die at a younger age compared with the general population. (1) (2) (3) (4) In the United Kingdom (UK) men with SMI die 8 to 15 years and women 7 to 18 years earlier than those without mental disorders. (1) This life expectancy gap is increasing. (2) Although suicide is an important cause of death in those with SMI, the majority of preventable deaths are due to chronic diseases, primarily cardiovascular, cerebrovascular, and respiratory disease. (2, 5) In England and Wales, people with schizophrenia have a three-fold greater risk of premature mortality compared with the general population.(5) Brown and colleagues (5) found that risk of unnatural deaths (violent deaths and suicide) declined significantly between 1982 and 2006, while the risk of premature death due to cardiovascular disease (CVD) more than doubled in comparison to the general population.
A complex web of factors contributes to this life expectancy gap. The side effects of psychotropic medications, particularly weight gain and impaired glucose tolerance, increase the risk of excess mortality in people with SMI directly through obesity and diabetes.(6) Unhealthy lifestyles include inactivity and diets that are high in fat and low in fruit and vegetables; these lifestyle factors may be consequences of negative symptoms of mental illness as well as poor emotional regulation. (7) In addition, there is a growing body of evidence that unequal healthcare provision contributes to the life expectancy gap. (8) Mental disorders are associated with poorer clinical management of disease.
People with SMI are less likely to receive timely and precise diagnosis because of 'diagnostic overshadowing', that is, physical complaints are overlooked and partially or totally attributed to psychological and psychiatric factors.(9) Differential access to effective care leads to poorer outcomes including preventable deaths(10) and incurs high costs in health care provision. (11) Although evidence-based interventions for improving chronic disease outcomes are available, there is little evidence of committed implementation for people with SMI. This may be driven by a lack of awareness of gaps in health-care by the service providers, and poor knowledge about the strength of the evidence for specific interventions. (9) Despite the extensive body of literature showing reduced life expectancy for people with severe mental illness, a comprehensive synthesis of existing evidence on interventions that might reduce mortality has not been attempted. This is necessary to guide practitioners and commissioners.
This meta-review aims to assess the evidence for the impact of health interventions in reducing excess mortality in people with SMI. Reviews were sought that examined trials that reported mortality, or physical health outcomes in people with SMI compared to those receiving 'usual care'.
As the major causes of excess deaths in people with SMI are chronic diseases, we focus on interventions that may impact on physiological health indicators for these conditions.
Methods

Search strategy
The review was conducted in 2014 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. (12) We focussed on existing syntheses of the literature in which authors had looked at the effect(s) of health interventions in people with SMI, generally defined in the mental/physical health literature as psychotic disorders (schizophrenia, schizoaffective and schizophrenia like illnesses), bipolar disorder and severe major depression, (13) and where mortality or physiological health parameters were reported as a primary outcome.
We used a broad search string (e.g., ['mental disorders' OR schizo* OR depress* OR bipolar*] AND [interventions OR treatment] AND [mortality OR survival]) to search: the Cochrane database of systematic reviews; the Database of abstracts of reviews of effects (DARE); the Campbell database of systematic reviews; and the Database of promoting health effectiveness reviews (DoPHER). We conducted additional searches of citation lists from research papers and reports to identify additional reviews. Specific databases searched and the search strings used are reported in the Appendix.
Inclusion/exclusion criteria
Systematic reviews were accepted if they included studies that compared an intervention versus control group conditions for people with SMI. Because reviews that included mortality or survival outcomes were scarce, secondary physiological outcomes associated with chronic diseases were also included: metabolic factors such as glycaemic control, dyslipidemia, and weight gain. We accepted any review that reported results of randomised controlled trials (RCTs), quasi-experimental studies and observational studies. Only reviews that employed a systematic search methodology and that reported effect sizes were included. No limitations were placed on language, date of publication, publication status. Reviews that only considered studies of individuals with pre-existing physical conditions, for instance cardiac patients, were excluded. Although this is an important area of research, causal direction is distinct in these patients compared with populations with SMI developing chronic diseases.
Synthesis methods
Titles and abstracts of all reviews were screened; relevant reviews were subjected to full text examination and were evaluated against the study criteria. Where multiple iterations of a review were found (e.g., a 2014 update was found for a 2013 Cochrane review (14, 15) ), only the most up-todate review was included. All reviews entering the study were downloaded into an EndNote database and duplicates were removed. Information describing study design, sample and comparison groups, interventions and outcome data were extracted from the full text. Two researchers (AJB and YK) independently extracted the data and where discrepancies were found, a third reviewer (MH) adjudicated differences. Types of interventions were identified and grouped into broad categories.
Given that meta-analyses were not possible due to heterogeneity in study design and focus, study findings were synthesised narratively to explore the impact of different types of interventions.
Quality assessment method
Review quality was assessed using AMSTAR,(16) a measurement tool developed specifically to assess the quality of systematic reviews with reference to the methodological and systematic rigour and synthesis of the evidence. The AMSTAR(16) enables the quality of a systematic review to be scored on the following 11 items (scoring as yes=1; no, can't answer or not applicable=0):
1. Was an a priori design provided? 2. Was there duplicate study selection and data extraction? 3. Was a comprehensive literature search performed? 4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 5. Was a list of studies (included and excluded) provided? 6. Were the characteristics of the included studies provided? 7. Was the scientific quality of the included studies assessed and documented? 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 9. Were the methods used to combine the findings of the studies appropriate? 10. Was the likelihood of publication bias assessed? 11. Was the conflict of interest stated?
The authors of the AMSTAR (16) provide guidance notes as to how each item is scored. This guidance was followed, with the exception of item 11, where clear acknowledgement of potential sources of support in the systematic review, rather than 'the review and the included studies' sufficed to be scored as 'yes'. The validity and reliability of AMSTAR have been established. (16, 17) 
Results
Systematic search findings
The database and citation searches yielded a total of 134 unique reviews. In total, 16 systematic reviews met the study criteria and entered the review (see Figure 1) . <Figure 1 about here> 6 The reviews showed substantial heterogeneity in terms of target groups, implementation strategy, and outcomes measures for the different categories of intervention. Of the 16 reviews included, eight identified mortality as an outcome of interest, including four that looked at both mortality and physiological health parameters, and another eight identified only physiological health parameters as outcomes.
The quality of the 16 review studies varied. Out of a total score of 11 on the AMSTAR, six reviews achieved scores of 9 or above, six achieved scores between 6 and 8, and four achieved scores of 5 or lower. As there is no recommended cut-off for the AMSTAR, we will refer to the reviews scoring 9 or above as 'high quality', to those scoring between 6-8 as 'medium quality', and to papers scoring 5 or lower as 'low quality'.
Overview of interventions
To facilitate comparisons of findings between reviews, we grouped similar intervention types into four broad categories: Interventions aimed at improving lifestyle-related risk factors in people with SMI can take a variety of forms. We broadly categorised these reviews as having a primary outcome of reducing risky lifestyle factors. Intervention modalities included pharmaceutical treatments and/or psycho-educational or behavioural approaches. These latter incorporate techniques such as problem solving, goal-setting and self-monitoring, sometimes with a practical component in terms of an exercise regime or dietary counselling. These are generally informed and adapted from existing lifestyle programs developed for use in the general population.
Findings of the reviews are summarised below by intervention category. Table 1 provides a summary of the study characteristics, findings and AMSTAR quality ratings for each of the reviews included.
Mental health interventions
We found two systematic reviews that focussed on mortality-related outcomes associated with use of psychiatric medications, specifically antipsychotics(19) and antidepressants. (20) Our search found one additional review that reported health outcomes of groups receiving psychological therapies. (21) The studies included in the two reviews looking at excess mortality and use of psychiatric medications A third high-quality review to look at mental health interventions and their effect on mortality reduction, examined the long-term effects of CBT in people with schizophrenia. The authors identified two trials reporting mortality as an outcome, neither of which found a significant association between CBT and risk of excess mortality. (21) We were unable to find any reviews that looked at the effect of psychotherapies (aimed at improving symptoms of mental disorders) on physiological health outcomes in people with depression or bipolar disorder.
<Table 1 about here>
Integrative community care
Two Cochrane reviews evaluated health outcomes in people with SMI allocated to integrative community care management (28) (28) found three RCTs that compared collaborative community health interventions versus standard care, producing a pooled RR of 0.47 (95%CI 0.17-1.34) for all-cause mortality. Although no results in either review were statistically significant, the authors report a general trend across the studies suggesting fewer deaths due to suicide/suspicious circumstances and few deaths overall in treatment groups.
Neither study reported physical health makers as outcomes of interest.
Interventions for lifestyle factors
We found 10 systematic reviews that measured health outcomes associated with lifestyle and behavioural interventions in people with SMI. Three reviews reported mortality as an outcome of interest, all of which scored highly on the AMSTAR scale. Studies identified in these reviews varied in terms of intervention types and outcome measures, and this hampered the ability to synthesise results; overall only four of the eleven reviews were able to report pooled effect sizes.(30-32, 36)
Overall, the reviews were consistent that interventions aimed at improving lifestyle factors can achieve modest but significant improvements in physical activity and eating habits.(38, 39). They
showed that interventions could effectively reduce antipsychotic-induced weight gain(31, 41, 42) and achieve weight loss/BMI reduction in those already overweight(31, 36-42). Where reviews looked both pharmacological treatment and behavioural interventions, both approaches were associated with a similar magnitude of improvement in weight and/or BMI control.(31, 41, 42)
Few studies evaluated interventions specifically designed to address outcomes such as metabolic syndrome, glycaemic control, dyslipidemia, blood pressure or other physiological markers of disease; these were considered as secondary measures to other outcomes and so analyses were often underpowered. The review by Tosh and Colleagues found one study that specifically evaluated a lifestyle program and its effect on physical health((35) reported in(30)). While there was no effect found for mediation of metabolic syndrome in people with SMI, there was a trend for fewer metabolic risks, from 13 to 10, after one year of follow-up. (30) A review by Gierisch and colleagues(31) found two out of the seven studies with glycaemic control as an outcome showed a significant improvement in the invention group over control group, in both cases metformin was prescribed as treatment. (31) Caemmerer and colleagues(36) conducted a meta-analysis, focussing on effects of nonpharmaceutical interventions. This medium quality study showed treatment was associated with a significant improvement in insulin levels (3 RCTs, WMD= -4.93 uIU/mL, p<0.001) and fasting glucose levels (6 RCTs, WMD= -5.79 mg/dL, p<0.001).(36) Interventions were also significantly associated with improved profiles for total cholesterol, LDL cholesterol and triglycerides, but the same was not found for HDL cholesterol or systolic blood pressure.(36) A brief mid-quality review by Cabassa(40) found 13 studies reporting metabolic risk measures, of which seven found statistically significant improvements in at least one physiological measure.
Screening and monitoring of health parameters
We identified only one review meeting our criteria that looked at screening and/or monitoring of physical health parameters in people with SMI. Tosh and colleagues (15) found no trials reporting the effects of health care monitoring (either self-monitoring or by a healthcare professional). The low AMSTAR score for this review reflects the lack of data available on the impact on health outcomes of physical health screening in people with SMI.
Discussion
We sought to synthesise the current scientific evidence on interventions that may reduce excess mortality or improve physical health indicators of chronic disease in people with SMI. We evaluated the evidence relating to four broad intervention categories: mental health interventions;
collaborative care interventions; interventions for risky lifestyle factors; and screening and monitoring of physical health parameters. Reviews suggest that psychiatric medications (antipsychotics and antidepressants) have some protective effect against excess mortality, but this is dependent on treatment adherence. Integrative community care programs may reduce physical morbidity and excess mortality associated with SMI, but the effective ingredients of the interventions need to be identified. Interventions to improve risky lifestyle behaviours can reduce the profile of risk factors, but studies with long-term outcomes are lacking. Screening and preventative interventions and improved care in those with comorbid chronic disease are expected to reduce excess mortality, however, there are currently no data available to support this. These findings highlight areas for policy, practice and research development. Below we explore the implications of our meta-review within the context of other research findings for each intervention category, taking into account a small number of studies post-dating the included systematic reviews.
Mental health interventions
We found the evidence on the effects of medication on mortality was equivocal. However a number of trials published subsequent to these reviews suggest that antipsychotics and antidepressants may be effective in reducing excess mortality but this is mediated by treatment adherence (44) (45) (46) . In Taking into account our findings, together with other research, we recommend further work is needed to identify the specific aspects of this approach that positively influence physical health.
Researchers hypothesise that benefits of care management are likely multi-factorial: clinicians may become more sensitive to changes in physical health outside the filter of the mental disorder diagnosis and patients may be more aware of health issues, have more frequent contact with health services, and be primed to seek treatment,(57) however evidence is lacking. Furthermore, as shortterm research funding tends to prelude robust investigation of mortality as an outcome, researchers and funding bodies need to invest in longer periods of intervention and follow-up of health outcomes.
Interventions for lifestyle factors
Overall, our meta-review shows that interventions to improve risky lifestyle behaviours can reduce individual's health risk profiles. One major limitation of studies in this intervention category was the short follow-up periods. This is important for two reasons. Firstly, this prevented us from drawing firm conclusions on the effectiveness of such programs in reducing mortality. Secondly, studies have shown that the positive effects of lifestyle interventions tend to deteriorate over time (43, 61) for people with SMI and the general population.(43) Given the motivational difficulties associated with medication effects and psychopathology, the SMI group faces additional challenges in instituting lifestyle changes. Papers identified in these reviews suggest that more tailored approaches to treatment with continued proactive follow-up by usual mental health clinicians will likely contribute to more prolonged long-term changes in healthy behaviours.
The 2011 British mental health outcomes strategy 'No Health without Mental Health' sets out 6 objectives shared at all levels of community and government.(62) It states one of its primary objectives as ensuring that "more people with mental health problems will have good physical health". However the commitments made to achieve this reflect a 'passive' approach, for instance improving nutritional standards in catering services, improving access to fitness facilities and developing alcohol and tobacco control plans. Given that the literature on lifestyle factors and collaborative care models suggests that proactive approaches tend to be more successful, these policies could be improved by integrating a component that ensures active follow-up by community service providers.
Screening and monitoring of health parameters
Screening, preventative interventions and improved physical health care for people with SMI and comorbid chronic disease are expected to reduce excess mortality, however there are currently no data available to support this. Nonetheless, available studies suggest there are inequities in terms of diagnostic timeliness, use of monitoring, and provision of physical health care interventions; each is considered below along with possible explanations.
Despite their increased exposure to chronic disease risk factors, many patients with SMI have limited access to general healthcare with less opportunity for metabolic risk factor screening and prevention (63) and lower rates of medical interventions than their counterparts in the general population.(64-67) Crump and colleagues (63) found that, despite their increased risk of mortality due to IHD and cancer, people with schizophrenia were less likely to receive diagnoses of IHD, hypertension, abnormal lipid levels, cancer or liver disease compared to those without schizophrenia.
After restricting the analysis to those previously diagnosed with chronic disease, schizophrenia was only modestly associated with IHD mortality and was no longer associated with cancer mortality. (63) This, in turn suggests that reducing the life expectancy gap for people with SMI also requires improvements in the coverage, timeliness, and quality of physical health care for this group.
Whilst there is still insufficient information to determine a causal link, indirect evidence supports the hypothesis that mortality in people with SMI may be averted, to some degree, through ensuring states that people with SMI should have an annual physical health check, preferably in primary care.
However, adherence to guidelines on screening and treatment of chronic disease is poor(74) and there is little information on why these barriers exist. Furthermore, the thresholds at which risk factor intervention is considered to be warranted are often determined by structured tools such as the QRISK2 (75) Strengths and weaknesses Some limitations should be acknowledged when considering these findings. This is a synthesis of reviews, based on systematic reviews published between 2007 and 2014. It therefore did not include some published trials conducted since these reviews were published, however we considered these when interpreting our findings and they did not alter our conclusions. A degree of judgement was required to classify some interventions into categories. This was because some reviews focussed on an intervention strategy (e.g., general medical advice), even though it formed part of a broader program while others brought together studies where care was delivered via specific platform (e.g., collaborative community care).
The quality of the included reviews varied substantially. Apart from the screening and monitoring of health parameters, however, all categories contained at least two reviews of good to high quality (scores of 8 or higher out of a maximum of 11) and scored on average between 7 and 9. Because of the variability of intervention strategies, outcome parameters, follow-up periods and statistical analyses it was not feasible to conduct statistical analyses necessary for meta-analysis.
A number of reviews were unable to be included because studies reported behavioural change outcomes but not physiological outcomes, for instance those looking at screening programs(81) and smoking cessation programs (43, (82) (83) (84) ). It may be that physiological outcomes are not measured in many cases due to the length of time it would take for any meaningful change in physical health to become apparent (for instance, in the case of smoking-related disease). However, to develop an evidence-base around programs that lead to improved health outcomes, physiological markers of change are required to enable us to draw more direct link between interventions and reduced premature mortality. This gap in our evidence synthesis highlights the importance of longitudinal follow-up of intervention outcomes to permit collection of physiological outcome measures.
Conclusion
The findings of this meta-review are important for practitioners, but also for commissioners and policy makers who set priorities and allocate resources. The health and financial implications of not intervening to reduce important causes of preventable deaths in people with SMI need recognition and remedy. The excess mortality rate is an important marker of general health among persons with SMI. The growing inequity in life expectancy, particularly due to heart disease mortality, underlines the need for better physical health care programs for this group. Two areas that warrant immediate action are: (1) improving adherence to psychiatric pharmacological guidelines; and (2) improving adherence to guidelines for monitoring metabolic health in those with SMI. There is an urgent need to improve the inequitable screening, monitoring and treatment of chronic disease in people with SMI. Research efforts should focus on filling major evidence gaps regarding the barriers to provision of physical health monitoring in persons with SMI and elucidating the aspects of integrative community care programs that have a positive impact on long-term health outcomes.
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